Name | Ceftobiprole medocaril |
---|---|
Synonyms |
Ceftobiprole medocaril
5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)-1-oxoethyl]amino]-3-[(E)-[(3'R)-1'-[[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]carbonyl]-2-oxo[1,3'-bipyrrolidin]-3-ylidene]methyl]-8-oxo-, (6R,7R)- (6R,7R)-7-{[(2Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)acetyl]amino}-3-{(E)-[(3'R)-1'-{[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]carbonyl}-2-oxo-1,3'-bipyrrolidin-3-ylidene]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid YXV28V1B07 Ceftobiprole medocaril free acid |
Description | Ceftobiprole medocaril is the parenteral prodrug of Ceftobiprole (HY-112579). Ceftobiprole is a broad-spectrum cephalosporin with activity against Methicillin-resistant staphylococcus aureus (MRSA). |
---|---|
Related Catalog | |
In Vivo | Ceftobiprole medocaril (10, 40, 160 mg/kg; single dose; sc) has T1/2s from 20 min to 31 min, as the dose rose from 40 mg/kg to 160 mg/kg. The AUC/dose values for the escalating single doses ranges from 0.585 to 1.33, and the Cmax/dose values decreases from 1.08 to 0.90 in neutropenic thigh-infected mice[1]. |
References |
Density | 2.0±0.1 g/cm3 |
---|---|
Molecular Formula | C26H26N8O11S2 |
Molecular Weight | 690.662 |
Exact Mass | 690.116272 |
LogP | -1.28 |
Index of Refraction | 1.865 |